EcoDrugPlus


Trade Names	ACTIN-N FURACIN NITROFURAZONE
Synonyms	Actin-n Furacilin Furacin Furacine Furazone NSC-1602 NSC-2100 Nitrofural Nitrofurazone
Status
Molecule Category	UNKNOWN
UNII	X8XI70B5Z6
EPA CompTox	DTXSID5020944

Trade Names

ACTIN-N

FURACIN

NITROFURAZONE

Synonyms

Actin-n

Furacilin

Furacin

Furacine

Furazone

NSC-1602

NSC-2100

Nitrofural

Nitrofurazone

Status

Molecule Category

UNKNOWN

UNII

X8XI70B5Z6

EPA CompTox

DTXSID5020944


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	IAIWVQXQOWNYOU-FPYGCLRLSA-N
Smiles	NC(=O)N/N=C/c1ccc([N+](=O)[O-])o1
InChI	InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+

InChI Key

IAIWVQXQOWNYOU-FPYGCLRLSA-N

Smiles

NC(=O)N/N=C/c1ccc([N+](=O)[O-])o1

InChI

InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+

Mechanism of Action	Action	Reference
DNA inhibitor	INHIBITOR	PubMed PubMed Wikipedia

Mechanism of Action

Action

Reference

DNA inhibitor

INHIBITOR

PubMed PubMed Wikipedia

Resources	Reference
ChEMBL	CHEMBL869
DrugBank	DB00336
DrugCentral	1950
FDA SRS	X8XI70B5Z6
Human Metabolome Database	HMDB0014480
KEGG	C08042
PDB	NFZ
PharmGKB	PA164754877
PubChem	5447130
SureChEMBL	SCHEMBL25416
ZINC	ZINC000000897369

Resources

Reference

ChEMBL

DrugBank

DrugCentral

FDA SRS

Human Metabolome Database

KEGG

PDB

PharmGKB

PubChem

SureChEMBL

ZINC


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

NITROFURAZONE

Structure

Pharmacology

Cross References